View a scientific, collaborative success with our client, Heat Biologics, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 medical oncology conference. We cover image analysis of tumor infiltrating lymphocytes (TIL) and more.
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
Tissue holds the answers in drug development; the question is how to read it consistently and at scale. Should your tissue be analyzed manually or digitally? Flagship may hold the answer.
Author(s): Maria Szwarc, Ph.D., Flagship Biosciences, Inc., Chandler S. Callaway, Ph.D., Flagship Biosciences, Inc., G. Dave Young, DVM, Flagship Biosciences, Inc., Nathaniel H. Atwood, B.S., Flagship Biosciences, Inc., Will Paces, MAS, Flagship Biosciences, Inc.,...
Abstract: The anti-PD-L1 antibody (22C3) is used as a companion diagnostic for successful checkpoint inhibitor therapy in head and neck squamous cell carcinoma. The positive predictive value of this assay, however, is less than ideal as a high PD-L1 score does not...
Key Takeaways CRC patient survival correlates with the presence or absence of macrophage biomarkers CD68, CD163, and a lack of PD-L1. Lower levels of ‘M1/anti-tumor’ CD68+ or CD68+CD163– cells correlate with increased survival. Higher levels of ‘M2/pro-tumor’ CD163+...
Key Takeaways Image analysis is able to use immune biomarkers to correlate immune cell presence and localization with patient survival in NSCLC. Patient survival correlates with the presence or absence of CD68 and CD163 macrophage markers, but these markers do not...